Cannabis and Science: The Dynamic Duo of Product Development with EndoCanna Health CEO, Len May

Key Insights

• DNA-guided personalization is the next frontier in cannabis product development: the same product produces dramatically different effects for different consumers based on individual genetics, endocannabinoid system function, and metabolic pathways - making personalized cannabis a science-backed approach with measurable business value for brands and dispensaries.
• Approximately 52% of the population carries a genetic predisposition that causes them to produce less anandamide than average due to a variant in the FAAH gene, which means roughly half of all cannabis consumers may have a baseline endocannabinoid deficiency that shapes their ideal product type, dose, and consumption format.
• How a consumer metabolizes cannabinoids depends on specific cytochrome P450 genes - CYP2C9 for THC, CYP2C19 for CBD, CYP3A4 for both - which means optimal timing, dose, and format are genetically variable and cannot be reliably predicted by product category or experience alone.
• The sativa/indica classification is an unreliable consumer guide because individual genetics affect the cannabis experience far more than broad product labels - and cannabis brands and dispensaries that lead with science-based product guidance rather than category labels will build more trust and generate better consumer outcomes.
• Even experienced cannabis users are essentially guessing when they select a product, and the market opportunity for brands is to use genetic and metabolic science to reduce inconsistent experiences, build evidence-based trust, and differentiate in a category where consumer frustration with unpredictable results remains high.

Webinar Highlights

00:00 – What EndoCanna Health Does and Why Genetics Matter

Len May introduces EndoCanna Health and the core concept: using DNA analysis to guide consumers toward cannabis products that match their specific genetics, endocannabinoid system function, and metabolic profile. The goal is to replace trial and error with science so consumers get consistent, predictable experiences instead of rolling the dice on every purchase.

08:00 – The Endocannabinoid System and Why Individual Response Varies

Len explains the endocannabinoid system and the concept of endocannabinoid deficiency - a condition where the body produces insufficient endocannabinoids internally. A variant in the FAAH gene affects approximately 52% of the population, causing them to produce less anandamide than average, which directly explains why two people can take the same product and have completely different experiences.

18:00 – How Cytochrome P450 Genes Control Cannabinoid Metabolism

The cytochrome P450 gene system determines how the body breaks down cannabinoids: CYP2C9 metabolizes THC, CYP2C19 handles CBD, and CYP3A4 processes both. Len explains why an isolated THC gummy follows a different metabolic pathway than a full-spectrum product - and why consumers using cannabis alongside prescription medications need to understand their specific metabolic speed to time use appropriately.

28:00 – Why Sativa and Indica Labels Fall Short

Consumer reliance on sativa/indica distinctions and strain names as purchase guidance is unreliable because individual genetics shape the experience far more than product category. Len explains why the same product can feel completely different for two people, and why the industry needs more scientifically grounded product guidance to reduce consumer frustration.

36:00 – Terpenes, Smell, and Personalized Product Matching

The conversation covers how terpene profiles interact with individual biology and how even smell perception is shaped by memory and personal context. When layered on top of genetic data, terpene-guided recommendations bring product selection closer to a precision match between product and consumer.

44:00 – The Consumer Education Opportunity for Cannabis Brands

Even experienced users are guessing when they pick a product. Len and Jake discuss the brand opportunity to use genetic and metabolic science to build trust, reduce consumer frustration with inconsistent experiences, and differentiate on evidence-based personalization rather than marketing claims and category labels.

Frequently Asked Questions

[ {What does EndoCanna Health do?}

EndoCanna Health is a health technology company that uses DNA analysis to guide consumers toward cannabis products that match their genetics, endocannabinoid system, and metabolic profile. Instead of trial and error, consumers receive science-backed recommendations for product type, cannabinoid ratios, and dosing based on their individual biology.

{What is endocannabinoid deficiency and how does it affect cannabis consumers?}

Endocannabinoid deficiency is a condition where the body produces insufficient endocannabinoids internally. A variant in the FAAH gene affects approximately 52% of the population, causing the body to produce less anandamide than average. This genetic predisposition directly shapes why some consumers need different product types, ratios, or doses than others to achieve consistent results.

{How does DNA affect cannabinoid metabolism?}

Specific cytochrome P450 genes determine how the body breaks down cannabinoids. CYP2C9 metabolizes THC, CYP2C19 handles CBD, and CYP3A4 processes both together. These genes also control how quickly a person metabolizes cannabinoids, which affects ideal dose, timing, and consumption format - especially for consumers using cannabis alongside prescription medications.

{Why do the same cannabis products affect people so differently?}

Individual genetics shape endocannabinoid system function, cannabinoid metabolism speed, terpene sensitivity, and receptor activity. Two people taking the same product can have entirely different experiences based on their unique biology. DNA-guided personalization addresses this by matching product recommendations to a consumer's specific genetic profile.

{Are sativa and indica labels reliable guidance for cannabis consumers?}

No. Sativa and indica labels are a poor predictor of how a specific product will affect a specific person. Individual genetics and metabolism play a far larger role than product category in determining the actual experience. More precise guidance - including cannabinoid ratios, terpene profiles, and metabolic compatibility - produces more reliable and repeatable consumer outcomes.

{How can cannabis brands use personalization science to differentiate?}

Brands that educate consumers on why individual biology drives cannabis response - and offer DNA-compatible product guidance, terpene matching, or metabolic profile tools - can stand out in a market where inconsistent consumer experiences are a widespread frustration. Science-backed personalization is a trust signal that generic product marketing cannot match.

{How should cannabis consumers manage cannabis use alongside prescription medications?}

The appropriate timing for cannabis use around prescription medications depends on individual metabolic speed. Ultra-rapid metabolizers may need to wait 30 to 40 minutes, while poor metabolizers may need several hours. Understanding your cytochrome P450 gene profile gives you the specific information needed to manage timing safely rather than guessing. ]